Literature DB >> 20930748

Peering into the aftermath: The inhospitable host?

Robert S Kerbel1, John M L Ebos.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20930748     DOI： 10.1038/nm1010-1084

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  14 in total

1.  Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers.

Authors:  A Lindauer; P Di Gion; F Kanefendt; D Tomalik-Scharte; M Kinzig; M Rodamer; F Dodos; F Sörgel; U Fuhr; U Jaehde
Journal:  Clin Pharmacol Ther       Date:  2010-04-07       Impact factor: 6.875

2.  Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.

Authors:  Petros G Nikolinakos; Nasser Altorki; David Yankelevitz; Hai T Tran; Shaoyu Yan; Dilip Rajagopalan; Walter Bordogna; Lone H Ottesen; John V Heymach
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

3.  Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment.

Authors:  G-One Ahn; Diane Tseng; Cho-Hwa Liao; Mary Jo Dorie; Agnieszka Czechowicz; J Martin Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

4.  Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.

Authors:  John M L Ebos; Christina R Lee; James G Christensen; Anthony J Mutsaers; Robert S Kerbel
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-17       Impact factor: 11.205

Review 5.  Biomarkers of response and resistance to antiangiogenic therapy.

Authors:  Rakesh K Jain; Dan G Duda; Christopher G Willett; Dushyant V Sahani; Andrew X Zhu; Jay S Loeffler; Tracy T Batchelor; A Gregory Sorensen
Journal:  Nat Rev Clin Oncol       Date:  2009-06       Impact factor: 66.675

Review 6.  Modes of resistance to anti-angiogenic therapy.

Authors:  Gabriele Bergers; Douglas Hanahan
Journal:  Nat Rev Cancer       Date:  2008-08       Impact factor: 60.716

7.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

8.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Authors:  Marta Pàez-Ribes; Elizabeth Allen; James Hudock; Takaaki Takeda; Hiroaki Okuyama; Francesc Viñals; Masahiro Inoue; Gabriele Bergers; Douglas Hanahan; Oriol Casanovas
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

Review 9.  Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.

Authors:  N Murukesh; C Dive; G C Jayson
Journal:  Br J Cancer       Date:  2009-12-15       Impact factor: 7.640

10.  Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.

Authors:  Samuel E Deprimo; Carlo L Bello; John Smeraglia; Charles M Baum; Dominic Spinella; Brian I Rini; M Dror Michaelson; Robert J Motzer
Journal:  J Transl Med       Date:  2007-07-02       Impact factor: 5.531
View more
  10 in total

1.  Cancer: Chemotherapy counteracted.

Authors:  Urban Emmenegger; Robert S Kerbel
Journal:  Nature       Date:  2010-12-02       Impact factor: 49.962

2.  Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer.

Authors:  Lee W Jones; Jodi Antonelli; Elizabeth M Masko; Gloria Broadwater; Christopher D Lascola; Diane Fels; Mark W Dewhirst; Jason R B Dyck; Jeevan Nagendran; Catherine T Flores; Allison S Betof; Erik R Nelson; Michael Pollak; Rajesh C Dash; Martin E Young; Stephen J Freedland
Journal:  J Appl Physiol (1985)       Date:  2012-05-17

Review 3.  The bed and the bugs: interactions between the tumor microenvironment and cancer stem cells.

Authors:  Zafira Castaño; Christine M Fillmore; Carla F Kim; Sandra S McAllister
Journal:  Semin Cancer Biol       Date:  2012-04-23       Impact factor: 15.707

4.  Notch1 regulates angio-supportive bone marrow-derived cells in mice: relevance to chemoresistance.

Authors:  Jeanine M L Roodhart; Huanhuan He; Laura G M Daenen; Arnaud Monvoisin; Chad L Barber; Miranda van Amersfoort; Jennifer J Hofmann; Freddy Radtke; Timothy F Lane; Emile E Voest; M Luisa Iruela-Arispe
Journal:  Blood       Date:  2013-05-20       Impact factor: 22.113

Review 5.  Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects.

Authors:  Yuval Shaked
Journal:  Nat Rev Clin Oncol       Date:  2016-04-26       Impact factor: 66.675

6.  Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors.

Authors:  Michalis Mastri; Christina R Lee; Amanda Tracz; Robert S Kerbel; Melissa Dolan; Yuhao Shi; John M L Ebos
Journal:  Mol Cancer Ther       Date:  2018-04-25       Impact factor: 6.261

7.  Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy.

Authors:  Lee W Jones; Diane R Fels; Miranda West; Jason D Allen; Gloria Broadwater; William T Barry; Lee G Wilke; Elisabeth Masko; Pamela S Douglas; Rajesh C Dash; Thomas J Povsic; Jeffrey Peppercorn; P Kelly Marcom; Kimberly L Blackwell; Gretchen Kimmick; Timothy G Turkington; Mark W Dewhirst
Journal:  Cancer Prev Res (Phila)       Date:  2013-07-10

Review 8.  The pro-tumorigenic host response to cancer therapies.

Authors:  Yuval Shaked
Journal:  Nat Rev Cancer       Date:  2019-10-23       Impact factor: 60.716

9.  Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities.

Authors:  Satish Sharan; Sukyung Woo
Journal:  Front Pharmacol       Date:  2015-02-20       Impact factor: 5.810

10.  Novel Molecular Mechanism of Aspirin and Celecoxib Targeting Mammalian Neuraminidase-1 Impedes Epidermal Growth Factor Receptor Signaling Axis and Induces Apoptosis in Pancreatic Cancer Cells.

Authors:  Bessi Qorri; William Harless; Myron R Szewczuk
Journal:  Drug Des Devel Ther       Date:  2020-10-08       Impact factor: 4.162
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.